Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Beclomethasone dipropionate
Drug ID BADD_D00219
Description Beclomethasone dipropionate is a second-generation synthetic corticosteroid agent [A179842] and a diester of beclomethasone, which is structurally similar to [dexamethasone].[L6871] It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP)[A179839] which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration.[A179839] Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray.[A179839] Due to its anti-inflammatory, antipruritic, and anti-allergy properties, beclomethasone dipropionate is used in various inflammatory conditions, such as asthma, allergic rhinitis, and dermatoses to reduce symptoms. When inhaled, it is proposed that beclomethasone dipropionate remains active locally in the lung without causing significant side effects associated with systemic corticosteroids.[A180010] Compared to earlier corticosteroids such as [dexamethasone] and [prednisolone], beclomethasone dipropionate is reported to be less irritating to the nasal mucosa with a longer duration of action when administered intranasally.[A179848]
Indications and Usage Used in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
Marketing Status Prescription; Discontinued
ATC Code A07EA07; D07AC15; R01AD01; R03BA01
DrugBank ID DB00394
KEGG ID D00689
MeSH ID D001507
PubChem ID 21700
TTD Drug ID D07DVK
NDC Product Code 51552-0883; 22552-0038; 38779-0364; 51927-1641; 59310-410; 52128-167; 49452-0802; 53104-7632; 52221-105; 65089-0010; 59310-406; 46439-8714
Synonyms Beclomethasone | Beclometasone | Asmabec Clickhaler | Ascocortonyl | Beclamet | Beclo Asma | Beclo AZU | Beclocort | Beclomet | Bemedrex Easyhaler | Beclomethasone Dipropionate | Dipropionate, Beclomethasone | Beclorhinol | Sanasthmax | Becloturmant | Beclovent | Beconase | Becloforte | Becodisk | Becodisks | Propaderm | Becotide | Sanasthmyl | Beconase AQ | Bronchocort | Junik | Qvar | Ecobec | Beclazone | Beclazone Easy Breathe | Ventolair | Prolair | Filair | Filair Forte | AeroBec Forte | Aerobec | Nasobec Aqueous | Respocort | Vancenase | Vanceril | Aldecin | Viarin | Apo-Beclomethasone
Chemical Information
Molecular Formula C28H37ClO7
CAS Registry Number 5534-09-8
SMILES CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Secondary adrenocortical insufficiency14.11.01.014; 05.01.02.003--Not Available
Sinusitis22.07.03.007; 11.01.13.0050.000546%
Skin atrophy23.01.05.001--
Skin discolouration23.03.03.0050.000364%Not Available
Skin striae23.01.05.002--Not Available
Sleep disorder19.02.04.001--Not Available
Sneezing22.02.05.0110.002728%
Suicidal ideation19.12.01.003--
Swelling face23.04.01.018; 10.01.05.0180.000364%Not Available
Syncope17.02.04.008; 02.01.02.008; 24.06.02.0120.000364%
Tachycardia02.03.02.0070.000728%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000546%Not Available
Tooth discolouration07.09.02.0010.000364%
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.0010.000909%
Visual impairment06.02.06.0080.000364%Not Available
Weight increased13.15.01.0060.000364%
Wheezing22.03.01.009--
Chapped lips07.05.01.0040.000364%Not Available
Oropharyngeal candidiasis22.07.03.003; 11.03.03.006; 07.05.07.003--Not Available
Rhinalgia22.02.05.0320.000364%Not Available
Nasal discomfort22.02.05.0200.006912%Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Growth retardation15.03.01.006--
Nasal disorder22.04.03.0040.000546%Not Available
Chorioretinopathy06.09.01.0060.000546%Not Available
Oral disorder07.05.01.005--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.000728%
Candida infection11.03.03.0210.001273%
The 3th Page    First    Pre   3    Total 3 Pages